Breaking News Instant updates and real-time market news.

OHRP

Ohr Pharmaceutical

$2.80

-0.03 (-1.06%)

06:16
10/04/16
10/04
06:16
10/04/16
06:16

Ohr Pharmaceutical assumed with a Hold at Brean Capital

Brean Capital analyst Jason Wittes assumed coverage of Ohr Pharmaceutical with a Hold rating.

OHRP Ohr Pharmaceutical
$2.80

-0.03 (-1.06%)

06/16/16
ROTH
06/16/16
INITIATION
Target $13
ROTH
Buy
Ohr Pharmaceutical resumed with a Buy at Roth Capital
Roth Capital analyst Joseph Pantginis resumed coverage of Ohr Pharmaceutical with a Buy rating and $13 price target.
08/10/16
BMUR
08/10/16
DOWNGRADE
BMUR
Hold
Ohr Pharmaceutical downgraded to Hold from Buy at Brean Capital
Brean Capital analyst Jonathan Aschoff downgraded Ohr Pharmaceutical to Hold citing concerns over the company's ability to fund its Phase 3 program as well as the increased frequency of background therapy in Phase 3 versus Phase 2.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.